Infectious Disease Billing: The PrEP, Ryan White and 340B Overlap Costing Practices Revenue in 2026

Three Payer Systems, One Claim: Why No-Cost PrEP Rules, Payer-of-Last-Resort Audits and 340B Program Integrity Reviews All Land on the Same Billing Desk

By Team Rcmaxis  ·  November 3, 2026  ·  13 min read

A commercially insured adult living with HIV costs a payer an average of $1,299,210 in discounted lifetime medical spending, against $181,481 for someone without HIV, according to a 2025 claims-data study published in PharmacoEconomics. Medicare's own antiretroviral drug bill for beneficiaries 65 and older is projected to climb from $6.4 billion in 2026 to $17.8 billion by 2035, per a JAMA Network Open analysis. Infectious disease billing isn't a niche corner of RCM. It's one of the highest dollar-per-claim specialties in medicine, and it runs on three overlapping payer systems that most billing teams were never trained to reconcile at the same time.

Here's the structural problem. A single HIV or hepatitis C patient encounter can touch a no-cost-sharing preventive mandate, a Ryan White Program funding rule that only applies after every other payer has been billed, and a 340B drug discount program that depends on your patient-eligibility records holding up to a federal audit. Miss any one of the three and you've either left money on the table, billed a patient who should never have seen a bill, or created exactly the documentation gap HRSA and HHS OIG know how to find.

Why Infectious Disease Claims Sit on Three Payer Systems at Once

Most specialties deal with one reimbursement model per visit. Infectious disease practices, especially HIV, PrEP and hepatitis C programs, routinely stack three. A PrEP patient's lab panel and prescription typically fall under the ACA's preventive services mandate, meaning no copay, no deductible, no coinsurance on a non-grandfathered plan. The same clinic's HIV-positive patients may be enrolled in a state ADAP or Ryan White Part B program, which legally cannot pay a claim until every other available payer has been billed and has either paid or issued a denial. And if your organization is a 340B covered entity, which a large share of Ryan White grantees and academic ID clinics are, the antiretroviral or antiviral drug itself may be purchased at a steep discount that comes with its own eligibility and duplicate-discount paperwork trail.

None of these three systems talks to the other two automatically. A clean claim under one framework can be a compliance problem under a second, which is exactly why infectious disease billing produces more audit findings per claim than almost any other specialty once a payer or a federal auditor starts pulling records.

The No-Cost PrEP Mandate Still Applies, and Billing Teams Still Get It Wrong

The Supreme Court settled the biggest open question around PrEP coverage on June 27, 2025, when it decided Kennedy v. Braidwood Management. The 6-3 ruling upheld the constitutionality of the U.S. Preventive Services Task Force, which means the Task Force's Grade A recommendation for PrEP, and the no-cost-sharing requirement that comes with an A or B grade under the ACA, stays in force for non-grandfathered plans. That's good news for patients and, in theory, straightforward for billers. In practice, it's not, because the mandate covers more than the drug itself: baseline and quarterly HIV testing (commonly billed with CPT 87389), the clinical visits tied to PrEP management, and the counseling that goes with it all have to be billed with no patient cost-sharing when the encounter is coded correctly.

The failure point is almost always the diagnosis or encounter code, not the CPT. If a claim doesn't carry the PrEP encounter diagnosis (ICD-10 Z29.81) or the visit gets coded as a routine office visit instead of a preventive encounter, most claims-adjudication systems will apply a standard cost-share by default, because nothing on the claim told the payer this was a mandated preventive service. That single coding gap is how patients end up getting billed for a service that was supposed to cost them nothing, which is both a revenue-cycle headache and, increasingly, the kind of complaint that draws state insurance-regulator attention. California's Department of Managed Health Care, for example, has published an explicit list of PrEP-related lab codes, including 87389, that health plans must cover without cost-sharing at baseline and at least every three months after that, and the state's own PrEP-AP assistance program caps reimbursement for that single test at $36.12, which gives you a sense of how thin the margin is if your clinic eats a cost-share it should never have billed in the first place.

Ryan White's Payer-of-Last-Resort Rule Is an Audit Trap, Not a Formality

If your clinic receives Ryan White HIV/AIDS Program or state ADAP funding, you already know the phrase "payer of last resort." What billing staff sometimes miss is how literally HRSA and HHS OIG mean it. The rule requires every other possible payer, private insurance, Medicaid, Medicare, or any other third-party source, to be billed first and to either pay the claim or formally deny it before Ryan White or ADAP dollars can be used to cover the balance. A clinic that skips the third-party verification step and bills Ryan White directly isn't just cutting a corner; it's creating the exact fact pattern that has triggered OIG findings against Ryan White grantees for over a decade.

This isn't theoretical risk. An August 2026 whistleblower report filed against the AIDS Task Force of the Upper Ohio Valley alleges that the organization billed its state ADAP program before checking whether patients had Medicaid, Medicare Part D, or TRICARE coverage that should have been billed first, and that in some cases ADAP and a second payer were both billed and both paid for the same medication, a double payment pattern that exposes federal programs to improper payments. A separate HHS OIG review of Ryan White Part B funding found that HRSA's own oversight of state-level payer-of-last-resort compliance had real gaps, which is a polite way of saying the agency responsible for catching this pattern wasn't always catching it either, before the states or grantees got audited directly.

340B and the New 2027 Reporting Requirement Every Covered Entity Needs on Its Calendar

340B doesn't change the CPT or HCPCS code on your claim, but it changes what has to be true behind that code. HRSA's own audit scope for covered entities checks three things: patient eligibility, duplicate discounts, and drug diversion. A duplicate discount happens when a 340B-purchased drug also gets a Medicaid rebate or a second discount it isn't entitled to, and it's one of the most common findings in HRSA compliance audits of covered entities. For infectious disease practices, where antiretrovirals and direct-acting antivirals for hepatitis C are both expensive and frequently 340B-eligible, the dollar exposure per error is larger than in most other drug categories.

The compliance bar is about to get higher, not lower. The CY 2027 Medicare Physician Fee Schedule final rule, which CMS released on November 4, 2026, requires 340B covered entities to submit Part D claims data for 340B-discounted drug units starting with dates of service on or after January 1, 2027, with the first mandatory quarterly submission, covering January 1 through March 31, 2027, due by September 30, 2027. That's a new, recurring federal data-submission obligation layered on top of the eligibility and duplicate-discount recordkeeping covered entities already have to maintain, and it gives HRSA and CMS a much cleaner dataset to cross-check against your 340B purchasing records than they've had before.

Hepatitis C Prior Authorization: What Actually Triggers Approval, and What Happens on Denial

Direct-acting antivirals for hepatitis C are curative in most patients within 8 to 12 weeks, but getting a payer to approve them still depends heavily on which state Medicaid program your patient is enrolled in. CMS has told states directly that restricting DAA access in ways that conflict with the drug-coverage requirements in Section 1927 of the Social Security Act is out of bounds, and several states, including Idaho, Massachusetts and New Hampshire, have dropped prior authorization requirements for most hepatitis C patients in response to that pressure and to outcomes data showing restrictions reduce treatment rates. Other states still require documentation of fibrosis stage, a negative or monitored substance-use screen, or prescriber specialty before a DAA claim clears. The dollar effect of loosening those rules shows up fast: in states that eased restrictions, Medicaid-covered DAA treatment courses rose from roughly 669 to 3,601 per 100,000 beneficiaries over a five-year stretch, which is the kind of volume swing that changes a specialty pharmacy's entire revenue forecast for the year.

The actionable part for your billing team: find out exactly what your state's current DAA policy requires before the claim goes out, not after it denies. If your state still requires a fibrosis-stage threshold, get that documented in the chart at the point of diagnosis, not retroactively. If sobriety or substance-use monitoring is a condition, make sure the note reflects the current screening result, not a stale one from months earlier. And track the prior-auth approval window separately from the treatment course length. A DAA prior authorization that expires before the full 8-to-12-week course finishes is a common, preventable reason a second half of a treatment course denies even though the first half was approved.

Building a Defensible Infectious Disease Billing Workflow

The fix across all three payer systems is the same discipline applied three different ways: verify eligibility and coverage rules before the claim goes out, document the specific fact that makes the claim defensible, and audit your own pattern on a schedule instead of waiting for a payer or a federal auditor to do it for you. For PrEP, that means confirming the encounter diagnosis and testing codes match the payer type, Medicare G-codes versus commercial CPT codes, before submission. For Ryan White and ADAP claims, it means a documented third-party verification step that happens every time, not when staff remember to run it. For 340B, it means a standing reconciliation process between your 340B purchase log and your Medicaid rebate data, done quarterly rather than only when HRSA sends an audit notice.

Our Part B drug billing guide covers the JW and JZ waste-reporting modifiers that also apply to infused antivirals and monoclonal therapies many ID practices administer, and our prior authorization guide walks through the broader documentation standards payers expect before approving a specialty drug course.

Frequently Asked Questions About Infectious Disease Billing

Does my practice have to bill PrEP services with no cost-sharing?

Yes, for most non-grandfathered plans. The Supreme Court's June 2025 ruling in Kennedy v. Braidwood Management kept the USPSTF's Grade A recommendation for PrEP intact, so the drug, the required baseline and follow-up HIV testing, and related counseling still have to be covered without a copay, deductible or coinsurance on ACA-compliant plans. The billing mistake isn't the mandate itself. It's a claims system that doesn't flag the PrEP encounter diagnosis code (Z29.81) and applies a standard cost-share by default.

What does payer of last resort mean for Ryan White-funded clinics?

It means Ryan White Program funds can only cover a service after every other available payer, Medicaid, Medicare, a commercial plan, or your state's ADAP, has been billed first and either paid or formally denied. A clinic that bills Ryan White or ADAP before checking third-party eligibility, or bills both and keeps both payments, is exactly the fact pattern HHS OIG and HRSA audits have flagged for years, and it's the core allegation in an August 2026 whistleblower complaint against an Ohio Valley AIDS service organization.

How does the 340B drug discount program affect my billing codes?

340B itself doesn't change your CPT or HCPCS codes, but it changes what HRSA and manufacturers expect your records to prove: that a drug billed under a 340B-discounted purchase wasn't also billed to a duplicate discount program like Medicaid rebates, and that the patient genuinely qualifies as a patient of the covered entity. Starting with dates of service on or after January 1, 2027, the CY 2027 Medicare Physician Fee Schedule final rule also requires covered entities to submit Part D claims data for 340B-discounted units, with the first quarterly submission due September 30, 2027, which raises the documentation bar further.